The activated MEK/ERK and AKT/mTOR signaling pathways have been found to increase Mcl-1 levels in AML cells [40-42] such that Mcl-1 is being considered as a therapeutic target for AML therapy [42]. This evidence concerns the gene AKT1 and acute myeloid leukemia.